Page last updated: 2024-11-13

rosamultin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rosamultin: isolated from roots of Rosa multiflora; RN not in Chemline 3/87; RN from Chem Abstracts Index Guide 1985 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
RosagenusA plant genus in the family ROSACEAE and order Rosales. This should not be confused with the genus RHODIOLA which is sometimes called roseroot.[MeSH]RosaceaeThe rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]

Cross-References

ID SourceID
PubMed CID21122581
CHEMBL ID501885
MeSH IDM0146394

Synonyms (12)

Synonym
88515-58-6
rosamultin
.beta.-d-glucopyranose, 1-o-[(2.alpha.,3.beta.)-2,3,19-trihydroxy-28-oxours-12-en-28-yl]-
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] (1r,2r,4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
S3287
CHEMBL501885
AC-35015
AKOS037515228
HY-N2565
CS-0022897
MS-30963
EX-A8013Q
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1072528Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072519Antiviral activity against Duck Hepatitis B virus infected in duckling assessed as decrease in DHBV DNA replication at 0.2 g/kg dosed for 10 days2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072523Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072527Selectivity index, ratio of cytotoxicity towards human HepG2.2.15 cells to IC50 for HBV e antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072522Selectivity index, ratio of cytotoxicity towards human HepG2.2.15 cells to IC50 for HBV surface antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072529Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1072521Selectivity index, ratio of cytotoxicity towards human HepG2.2.15 cells to IC50 for HBV DNA production2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's2 (22.22)18.2507
2000's3 (33.33)29.6817
2010's1 (11.11)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.80 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]